Sarepta COO Buys 1,875 PSUs Amid 26% Monthly Decline, Signaling Executive Optimism in a Volatile Biotech Market
Executive insider buying at Sarepta Therapeutics signals confidence amid a 26% monthly share decline, highlighting potential for pipeline growth and shareholder alignment.
3 minutes to read